FoundationOne® Liquid CDx helps guide treatment strategies for advanced cancer patients by analyzing 300+ genes from just two tubes of blood — making it the most comprehensive FDA-approved liquid biopsy on the market.

Companion diagnostic claims across multiple targeted therapies and cancer indications have been demonstrated through clinical outcomes data.

**Coverage and Patient Access:**
- Qualifying Original Medicare beneficiaries have no out-of-pocket costs for FoundationOne Liquid CDx.
- 84% of patients have $0 financial responsibility for Foundation Medicine testing.
- As part of our FoundationAccess™ program, for each comprehensive genomic profiling test ordered, we complete a benefits investigation and reach out to all patients whom we expect may have out-of-pocket costs.

**Comprehensive Panel Analyzes**

- **324 genes**:* from two tubes of blood, providing comprehensive results typically within 10 days† to help inform treatment strategies.
- Includes results from genomic signatures:
  - Blood Tumor Mutational Burden (bTMB)‡
  - Microsatellite Instability High (MSI-H)І
  - Tumor FractionІ

**Improved Outcomes**

In the TRITON2 Clinical Trial, 46% Objective Response Rate for advanced prostate cancer patients who tested positive for BRCA1/2 alterations and treated with RUBRACA* (rucaparib).І

**Actionable Insights**

67% of patients received a FoundationOne Liquid CDx report with a recommended therapy in their tumor type, a recommended therapy in another tumor type, or a clinical trial option.І

---

*FoundationOne® Liquid CDx is FDA-approved to report substitutions and indels in 311 genes, including rearrangements in ALK and BRCA1/2 and copy number alterations in BRCA1/2 and ERBB2 (HER2). Comprehensive results across all 324 genes are reported as a laboratory professional service which is not reviewed or approved by the FDA.

†From receipt of specimen and complete order.

‡bTMB, MSI-H status, and tumor fraction are reported as a laboratory professional service which is not reviewed or approved by the FDA.

ІFrom receipt of specimen and complete order.

FOR MORE DETAILED INFORMATION VISIT foundationmedicine.com/F1LCDx
Includes Clinically Relevant Genes and Biomarkers

For full list of 324 genes, visit foundationmedicine.com/F1LCDx

<table>
<thead>
<tr>
<th>TUMOR TYPES</th>
<th>BIOMARKER(S) DETECTED</th>
<th>THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-Small Cell Lung Cancer (NSCLC)</strong></td>
<td><strong>EGFR</strong> exon 19 deletions and <strong>EGFR</strong> exon 21 L858R substitution</td>
<td><strong>IRESSA</strong> (gefitinib), <strong>TAGRISSO</strong> (osimertinib) or <strong>TARCEVA</strong> (erlotinib)</td>
</tr>
<tr>
<td></td>
<td><strong>ALK</strong> rearrangements</td>
<td><strong>ALECENSA</strong> (alectinib)</td>
</tr>
<tr>
<td></td>
<td><strong>MET</strong> single nucleotide variants (SNVs) and indels that lead to <strong>MET</strong> exon 14 skipping</td>
<td><strong>TABRECTA</strong> (capmatinib)</td>
</tr>
<tr>
<td><strong>Ovarian Cancer</strong></td>
<td><strong>BRCA1/2</strong> alterations</td>
<td><strong>RUBRACA</strong> (rucaparib)</td>
</tr>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td><strong>BRCA1, BRCA2, ATM</strong> alterations</td>
<td><strong>LYNPARZA</strong> (olaparib)</td>
</tr>
<tr>
<td></td>
<td><strong>BRCA1, BRCA2, ATM</strong> alterations</td>
<td><strong>RUBRACA</strong> (rucaparib)</td>
</tr>
</tbody>
</table>

Tarceva® is the registered trademark of OSI Pharmaceuticals, LLC. Iressa®, Lynparza®, and Tagrisso® are registered trademarks of the AstraZeneca group of companies. Piqray® and Tabrecta® are registered trademarks of Novartis AG Corporation Switzerland. Rubraca® is a registered trademark of Clovis Oncology, Inc.

FoundationOne® Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reffed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

References
2. Medicare and Medicare Advantage members have coverage in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria.
3. Based on US clinical tests reported between September 1, 2020 and June 1, 2021. Data current as of July, 2021. Only one sample per patient included. For patients who received multiple tests, the most recent test result was used.